| TAXES ON INCOME [Text Block] |
| NOTE 19:- |
TAXES ON INCOME
|
| |
a. |
Tax rates applicable to the Group:
|
| |
1. |
The Company is subject to tax rates applicable in Canada. The combined federal and provincial rate for 2023 and 2022 is 26.5%.
|
| |
2. |
The Israeli subsidiaries are subject to Israeli corporate income tax rate of 23% in 2023 and 2022.
|
| |
3. |
The German subsidiary is subject to weighted tax rate of approximately 29.1% (composed of Federal and Municipal tax).
|
| |
b. |
Carryforward losses for tax purposes:
Carryforward operating tax losses of the Israeli subsidiaries total approximately $8,000, as of December 31, 2023. These losses can be carried forward to future years and offset against taxable income in the future without any time limitation. The company did not record deferred tax assets with regards to IMC, Focus and I.M.C. Pharma Ltd. since the Companies does not anticipate to utilize the net operating losses in the foreseeable future.
Carryforward operating tax losses of the German subsidiary as of December 31, 2023, amounted to approximately $15,599. Accumulated tax losses can be carried forward without time restrictions and can be deducted from future profits and capital gains unless they exceed €1,000 thousand (approximately $1,465). Any excess of such amount will be limited to 60% of the profits or capital gains. Unused carried forward losses will be subject to such limitation in the future. No deferred tax assets were recorded with regards to the German subsidiary since the Company does not anticipate to utilize the net operating losses in the foreseeable future.
|
| |
c. |
Income tax expense (benefit): |
| |
|
|
| |
|
Year ended December 31,
|
|
| |
|
2023
|
|
|
2022
|
|
|
2021
|
|
| |
|
|
|
|
|
|
|
|
|
|
Current
|
|
$
|
182
|
|
|
$
|
688
|
|
|
$
|
243
|
|
|
Deferred, net
|
|
|
394
|
|
|
|
(1,810
|
)
|
|
|
278
|
|
|
Income tax from previous years
|
|
|
195
|
|
|
|
(16
|
)
|
|
|
(21
|
)
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
$
|
771
|
|
|
$
|
(1,138
|
)
|
|
$
|
500
|
|
| |
|
December 31,
|
|
| |
|
2023
|
|
|
2022
|
|
|
Deferred tax assets:
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
Carryforward tax losses and other
|
|
$
|
-
|
|
|
$
|
731
|
|
|
Other deferred tax assets
|
|
|
-
|
|
|
|
32
|
|
| |
|
|
|
|
|
|
|
|
| |
|
|
-
|
|
|
|
763
|
|
|
Deferred tax liabilities:
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
Intangible assets
|
|
|
963
|
|
|
|
1,285
|
|
|
Other
|
|
|
-
|
|
|
|
47
|
|
| |
|
|
|
|
|
|
|
|
| |
|
|
963
|
|
|
|
1,332
|
|
| |
|
|
|
|
|
|
|
|
|
Deferred tax liabilities, net
|
|
$
|
(963
|
)
|
|
$
|
(569
|
)
|
The deferred taxes are reflected in the statements of financial position as follows:
| |
|
December 31,
|
|
| |
|
2023
|
|
|
2022
|
|
| |
|
|
|
|
|
|
|
Non-current assets
|
|
$
|
-
|
|
|
$
|
763
|
|
| |
|
|
|
|
|
|
|
|
|
Non-current liabilities
|
|
$
|
963
|
|
|
$
|
1,332
|
|
The deferred taxes are computed based on the tax rates that are expected to apply upon realization.
| |
e. |
Reconciliation of tax expense (benefit) and the accounting loss multiplied by the Company's domestic tax rate for:
|
| |
|
Year ended December 31,
|
|
| |
|
2023
|
|
|
2022
|
|
|
2021
|
|
| |
|
|
|
|
|
|
|
|
|
|
Loss before income tax
|
|
$
|
(9,457
|
)
|
|
$
|
(26,060
|
)
|
|
$
|
(164
|
)
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Statutory tax rate in Canada 26.5%
|
|
|
(2,506
|
)
|
|
|
(6,906
|
)
|
|
|
(43
|
)
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Increase (decrease) in income tax due to:
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-deductible expenses (non-taxable income), net for tax purposes
|
|
|
(122
|
)
|
|
|
1,764
|
|
|
|
(4,208
|
)
|
|
Effect of different tax rate of subsidiaries
|
|
|
169
|
|
|
|
599
|
|
|
|
310
|
|
|
Adjustments in respect of current income tax of previous years
|
|
|
195
|
|
|
|
(16
|
)
|
|
|
(21
|
)
|
|
Recognition (derecognition) of tax benefit in respect of losses of previous years
|
|
|
1,565
|
|
|
|
-
|
|
|
|
846
|
|
|
Unrecognized tax benefit in respect of loss for the year
|
|
|
1,432
|
|
|
|
4,037
|
|
|
|
4,093
|
|
|
Other adjustments
|
|
|
38
|
|
|
|
(616
|
)
|
|
|
(477
|
)
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Income tax expense (benefit)
|
|
$
|
771
|
|
|
$
|
(1,138
|
)
|
|
$
|
500
|
|
|